New combo therapy shows promise in halting lung cancer return
NCT ID NCT03110978
First seen Nov 03, 2025 · Last updated Apr 25, 2026 · Updated 23 times
Summary
This study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation (SABR) can better prevent lung cancer from coming back or spreading, compared to radiation alone. About 140 adults with early-stage non-small cell lung cancer or a single recurrence in the lung are participating. The goal is to see if the combination improves how long patients stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
MD Anderson West Houston
Houston, Texas, 77079, United States
-
MD Anderson in The Woodlands
Conroe, Texas, 77384, United States
Conditions
Explore the condition pages connected to this study.